Merck Investors' Claims Time-Barred, 3rd Circ. Finds
The Third Circuit Wednesday found a June U.S. Supreme Court ruling established investors' claims that Merck & Co. Inc. misrepresented results of a clinical trial of its anti-cholesterol drug Vytorin were...To view the full article, register now.
Already a subscriber? Click here to view full article